Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

T-regulatory cells: key players in tumor immune escape and angiogenesis.

Facciabene A, Motz GT, Coukos G.

Cancer Res. 2012 May 1;72(9):2162-71. doi: 10.1158/0008-5472.CAN-11-3687. Review.

2.

Induced regulatory T cells in inhibitory microenvironments created by cancer.

Whiteside TL.

Expert Opin Biol Ther. 2014 Oct;14(10):1411-25. doi: 10.1517/14712598.2014.927432. Epub 2014 Jun 17. Review.

3.

T regulatory cells in cancer: recent advances and therapeutic potential.

Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE.

Expert Opin Biol Ther. 2010 Nov;10(11):1573-86. doi: 10.1517/14712598.2010.529126. Review.

PMID:
20955112
4.

Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.

Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J.

J Immunol. 2010 Jun 15;184(12):6833-42. doi: 10.4049/jimmunol.0904084. Epub 2010 May 7.

5.

Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.

Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW.

J Leukoc Biol. 2006 Dec;80(6):1183-96. Epub 2006 Sep 22. Review.

PMID:
16997855
6.

Functions of thymic stromal lymphopoietin in non-allergic diseases.

Ying G, Zhang Y, Tang G, Chen S.

Cell Immunol. 2015 Jun;295(2):144-9. doi: 10.1016/j.cellimm.2015.03.006. Epub 2015 Mar 23. Review.

PMID:
25880106
7.

Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.

Ning H, Shao QQ, Ding KJ, Gao DX, Lu QL, Cao QW, Niu ZH, Fu Q, Zhang CH, Qu X, Lü JJ.

Chin Med J (Engl). 2012 Jun;125(12):2120-5.

PMID:
22884140
8.

Basic principles of tumor-associated regulatory T cell biology.

Savage PA, Malchow S, Leventhal DS.

Trends Immunol. 2013 Jan;34(1):33-40. doi: 10.1016/j.it.2012.08.005. Epub 2012 Sep 19. Review.

9.

Immunosuppressive strategies that are mediated by tumor cells.

Rabinovich GA, Gabrilovich D, Sotomayor EM.

Annu Rev Immunol. 2007;25:267-96. Review.

10.

How do tumors actively escape from host immunosurveillance?

Wilczyński JR, Duechler M.

Arch Immunol Ther Exp (Warsz). 2010 Dec;58(6):435-48. doi: 10.1007/s00005-010-0102-1. Epub 2010 Oct 5. Review.

PMID:
20922572
11.

Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape.

Wang H, Pan K, Xia JC.

Ai Zheng. 2009 Feb;28(2):184-7. Epub 2009 Feb 12. Review.

PMID:
19550135
12.

Regulatory T cells and immune tolerance to tumors.

Cao X.

Immunol Res. 2010 Mar;46(1-3):79-93. doi: 10.1007/s12026-009-8124-7. Review.

PMID:
19763889
13.

Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients.

Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX, Cai XY, He HW, Jin JJ, Cheng YF, Fan J, Sun J, Qiu SJ.

J Gastroenterol Hepatol. 2013 Sep;28(9):1555-64. doi: 10.1111/jgh.12202.

PMID:
23517245
14.

Inhibitory receptors as targets for cancer immunotherapy.

Turnis ME, Andrews LP, Vignali DA.

Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413. Review.

15.

Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.

Kandalaft LE, Motz GT, Busch J, Coukos G.

Curr Top Microbiol Immunol. 2011;344:129-48. doi: 10.1007/82_2010_95. Review.

PMID:
20680802
16.

Emerging roles of regulatory T cells in tumour progression and metastasis.

Halvorsen EC, Mahmoud SM, Bennewith KL.

Cancer Metastasis Rev. 2014 Dec;33(4):1025-41. doi: 10.1007/s10555-014-9529-x. Review.

PMID:
25359584
17.

Tumor-specific regulatory T cells in cancer patients.

Piersma SJ, Welters MJ, van der Burg SH.

Hum Immunol. 2008 Apr-May;69(4-5):241-9. doi: 10.1016/j.humimm.2008.02.005. Epub 2008 Mar 28. Review.

PMID:
18486758
18.
19.

Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force.

Hatziioannou A, Alissafi T, Verginis P.

J Leukoc Biol. 2017 Aug;102(2):407-421. doi: 10.1189/jlb.5VMR1116-493R. Epub 2017 Mar 30. Review.

PMID:
28360184
20.

Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.

Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS.

Int J Oncol. 2010 Apr;36(4):841-8.

PMID:
20198327

Supplemental Content

Support Center